Abivax (ABVX) Stock Price, News & Analysis

Company Overview

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Key Stats

• Today's Range: $6.52 to $7.15
• 50-Day Range: $5.67 to $8.19
• 52-Week Range: $4.77 to $14.16
• Volume: 180,531 shs
• Average Volume: 158,158 shs
• Market Capitalization: $447.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.00
• Consensus Rating: Buy

Abivax Stock Analysis - MarketRank™

Abivax scored higher than 44% of companies evaluated by MarketBeat, and ranked 662nd out of 931 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Abivax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Abivax has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Abivax are expected to grow in the coming year, from ($2.83) to ($2.57) per share.

Price to Book Value per Share Ratio

Abivax has a P/B Ratio of 10.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.27% of the float of Abivax has been sold short.

Short Interest Ratio / Days to Cover

Abivax has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Abivax has recently increased by 6.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Abivax does not currently pay a dividend.

Dividend Growth

Abivax does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.27% of the float of Abivax has been sold short.

Short Interest Ratio / Days to Cover

Abivax has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Abivax has recently increased by 6.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 1.36

News Sentiment

Abivax has a news sentiment score of 1.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Abivax this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Abivax insiders have not sold or bought any company stock.

Percentage Held by Institutions

47.91% of the stock of Abivax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ABVX Stock Analysis - Frequently Asked Questions

How have ABVX shares performed this year?

Abivax's stock was trading at $7.32 at the beginning of the year. Since then, ABVX shares have decreased by 3.7% and is now trading at $7.05.
View the best growth stocks for 2025 here.

When did Abivax IPO?

Abivax (ABVX) raised $217 million in an IPO on Friday, October 20th 2023. The company issued 18,699,460 shares at $11.60 per share.

Who are Abivax's major shareholders?

Top institutional investors of Abivax include ADAR1 Capital Management LLC (3.48%), Nantahala Capital Management LLC (2.34%), Octagon Capital Advisors LP (1.94%) and Allostery Investments LP (1.73%).

How do I buy shares of Abivax?

Shares of ABVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Abivax own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abivax investors own include Adverum Biotechnologies (ADVM), APi Group (APG), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Boot Barn (BOOT), G1 Therapeutics (GTHX) and Howard Hughes (HHH).

Company Calendar

• Today: 6/25/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABVX
• Previous Symbol: NASDAQ:ABVX
• CIK: 1956827
• Web: www.abivax.com
• Phone: 33-1-53-83-09-63
• Fax: N/A
• Employees: 61
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.00
• High Stock Price Target: $48.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +341.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.29
• Current Ratio: 1.25
• Quick Ratio: 1.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 10.19

Miscellaneous

• Outstanding Shares: 63,450,000
• Free Float: N/A
• Market Cap: $446.05 million
• Optionable: Not Optionable
• Beta: 0.01